74053-94-4

Basic information

• Product Name: ETHYL [3,4-(ETHYLENEDIOXY)BENZOYL]ACETATE
• Synonyms: ETHYL [3,4-(ETHYLENEDIOXY)BENZOYL]ACETATE
• CAS NO: 74053-94-4
• Molecular Formula: C₁₃H₁₄O₅
• Molecular Weight: 250.25
• Mol File: 74053-94-4.mol
• Article Data: 5

Chemical Properties

• Boiling Point: 377.1±42.0 °C(Predicted)
• Appearance: /
• Density: 1.233±0.06 g/cm3(Predicted)
• PKA: 10.76±0.20(Predicted)
• CAS DataBase Reference: ETHYL [3,4-(ETHYLENEDIOXY)BENZOYL]ACETATE(CAS DataBase Reference)
• NIST Chemistry Reference: ETHYL [3,4-(ETHYLENEDIOXY)BENZOYL]ACETATE(74053-94-4)
• EPA Substance Registry System: ETHYL [3,4-(ETHYLENEDIOXY)BENZOYL]ACETATE(74053-94-4)

Safety Data

• Hazardous Substances Data: 74053-94-4(Hazardous Substances Data)

Upstream product

• 2879-20-1 1,4-benzodioxan-6-yl methyl ketone 
• 105-58-8 Diethyl carbonate 
• 1197-09-7 1-(3,4-dihydroxyphenyl)ethan-1-one 
• 4442-54-0 2,3-dihydro-1,4-benzodioxin-6-carboxylic acid 
• 64-17-5 ethanol 
• 1404449-41-7 5-(2,3-dihydrobenzo[b][1,4]dioxine-6-carbonyl)-2,2-dimethyl-1,3-dioxane-4,6-dione 
• 6148-64-7 ethyl potassium malonate 
• 6761-70-2 2,3-dihydro-1,4-benzodioxine-6-carbonyl chloride 
• 1282295-32-2 C₁₂H₁₀N₂O₃ 

Downstream Products

• 491833-28-4 (1R,2R)-2-amino-1-(2,3-dihydrobenzo[β][1,4]dioxin-6-yl)-3-pyrrolidin-1-yl-propan-1-ol 
• 491833-29-5 (1R,2R)-octanoic acid [2-(2',3'-dihydro-benzo[1,4]dioxin-6'-yl)-2-hydroxy-1-pyrrolidin-1-ylmethyl-ethyl]-amide 
• 1607425-77-3 2-benzyl-5-(2,3-dihydrobenzo[b][1,4]dioxin-6-yl)-[1,2,4]triazolo[1,5-a]pyrimidin-7(4H)-one 
• 1404447-17-1 5-(2,3-dihydrobenzo[b][1,4]dioxin-6-yl)-3-(3-fluorophenyl)pyrazolo[1,5-a]pyrimidin-7(4H)-one 
• 1404447-12-6 5-(2,3-dihydrobenzo[b][1,4]dioxin-6-yl)-3-(4-fluorophenyl)pyrazolo[1,5-a]pyrimidin-7(4H)-one 
• 1404447-07-9 5-(2,3-dihydrobenzo[b][1,4]dioxin-6-yl)-3-(4-fluorophenyl)-2-methylpyrazolo[1,5-a]pyrimidin-7(4H)-one 
• 1404447-11-5 5-(2,3-dihydrobenzo[b][1,4]dioxin-6-yl)-3-(4-methoxyphenyl)-2-methylpyrazolo[1,5-a]pyrimidin-7(4H)-one 
• 1404447-29-5 5-(2,3-dihydrobenzo[b][1,4]dioxin-6-yl)-2-hydroxy-3-phenylpyrazolo[1,5-a]pyrimidin-7(4H)-one 
• 1404447-43-3 5-(2,3-dihydrobenzo[b][1,4]dioxin-6-yl)-3-phenyl-2-(trifluoromethyl)pyrazolo[1,5-a]pyrimidin-7(4H)-one 
• 1404447-30-8 3-(4-bromophenyl)-5-(2,3-dihydrobenzo[b][1,4]dioxin-6-yl)pyrazolo[1,5-a]pyrimidin-7(4H)-one 
• 1404446-58-7 5-(2,3-dihydrobenzo[b][1,4]dioxin-6-yl)-3-phenylpyrazolo[1,5-a]pyrimidin-7(4H)-one 
• 1404446-60-1 5-(2,3-dihydrobenzo[b][1,4]dioxin-6-yl)-2-methyl-3-phenylpyrazolo[1,5-a]pyrimidin-7(4H)-one 
• 1404447-08-0 5-(2,3-dihydrobenzo[b][1,4]dioxin-6-yl)-3-(4-methoxyphenyl)pyrazolo[1,5-a]pyrimidin-7(4H)-one 
• 1404447-18-2 5-(2,3-dihydrobenzo[b][1,4]dioxin-6-yl)-3-(3-methoxyphenyl)pyrazolo[1,5-a]pyrimidin-7(4H)-one 

Relevant articles and documents

Eliglustat intermediate and preparation method thereof

The invention relates to an eliglustat intermediate and a preparation method thereof, and provides a series of intermediate compounds for preparing eliglustat, and a preparation method of the intermediates. With the method provided by the invention, raw materials and a transition metal catalyst are subjected to an asymmetric hydrogenation reaction on under certain conditions, and then a series ofreactions are performed to prepare eliglustat. The method provided by the invention is simple and controllable in reaction conditions and easy for industrial production.

HETEROCYCLIC COMPOUNDS FOR THE INHIBITION OF PASK

Disclosed herein are new heterocyclic compounds and compositions and their application as pharmaceuticals for the treatment of disease. Methods of inhibiting PAS Kinase (PASK) activity in a human or animal subject are also provided for the treatment of diseases such as diabetes mellitus.

Pyrrolidine-3-carboxylic acids as endothelin antagonists. 2. Sulfonamide-based ET(A)/ET(B) mixed antagonists

When the N,N-dialkylacetamide side chain of the highly ET(A)-selective endothelin antagonist ABT-627 (1; [2R,3R,4S]-2-(4-methoxyphenyl)-4-(1,3- benzodioxol-5-yl)-1-[[(N,N-dibutylamino)carbonyl]methyl]pyrrolidine-3- carboxylic acid; A-147627) is replaced by N,S-dialkylsulfonami-doethyl, the resultant analogs retain ET(A) affinity, but exhibit substantial ET(B) affinity as well. Structure-activity studies reveal that modifications in the length of the two alkyl groups, and in the substitution on the anisyl ring, are important in optimizing this 'balanced' antagonist profile. In particular the combination of an N-n-propyl group, an S-alkyl chain between four and six carbons in length, and a fluorine atom ortho to the aromatic OCH3 provides compounds with sub-nanomolar affinities for both receptor subtypes, and with ET(A)/ET(B) ratios close to 1. A number of these compounds also exhibit oral bioavailabilities (in rats) in the 30-50% range and have substantial plasma half-lives. The balanced receptor-binding profile of these potent and orally bioavailable compounds complements the ET(A) selectivity observed with 1.